Barclays
STAB

Barclays’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Barclays’s Portfolio STAB Stock Details STAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7,600
Closed -$26K – 5334
2020
Q4 		$26K Hold
7,600
– – ﹤0.01% 4627
2020
Q3 		$15K Sell
7,600
-36,850
-83% -$84.9K ﹤0.01% 4948
2020
Q2 		$114K Buy
+44,450
New +$80.3K ﹤0.01% 4432
2020
Q1 		– Sell
-18
Closed – – 6600
2019
Q4 		$0 Buy
+18
New +$13 ﹤0.01% 6995

Other funds holding STAB

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Barclays's STAB Position: Q1 2021 in Review

Barclays sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q1 2021, closing a stake of 7,600 shares — an estimated $26K sold.

Barclays first reported a position in STAB in Q4 2019 and held it in 4 quarters. The position peaked at $114K in Q2 2020. 22 funds tracked by Wall St. Rank hold STAB as of Q1 2021.

  • Barclays reported no remaining Statera Biopharma, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Barclays sold 7,600 Statera Biopharma, Inc. Common Stock shares in Q1 2021, an estimated $26K.
  • Barclays first reported a position in Statera Biopharma, Inc. Common Stock in Q4 2019 and held it in 4 quarters.
  • Barclays's Statera Biopharma, Inc. Common Stock position peaked at $114K in Q2 2020.
  • 22 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q1 2021.

Based on Barclays's 13F filing for Q1 2021, filed 13 May 2021.